DTX3L Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with disrupted DTX3L gene expression, enabling loss-of-function investigation of this E3 ubiquitin ligase in a widely used human embryonic kidney cell model. The polyclonal format provides a heterogeneous collection of edited cells, avoiding clonal bias while ensuring robust knockout effects across the population.
HEK293T cells originated from human embryonic kidney epithelium transformed with adenovirus 5 DNA and constitutively express the SV40 large T antigen. This enables episomal plasmid replication and yields exceptionally high transfection efficiency and recombinant protein production, making HEK293T a premier host for viral packaging, biochemical reconstitution, and cell-based assays.
DTX3L encodes a RING-type E3 ligase that partners with PARP9 to mediate ubiquitination of target proteins, prominently histone H4. The DTX3L-PARP9 complex is transcriptionally induced by interferon-?? (IFN-??) through the JAK-STAT pathway: IFN-?? receptor engagement activates JAK1/2 kinases, leading to STAT1 phosphorylation, nuclear translocation, and cooperative binding with IRF1 at the DTX3L promoter. NF-??B further augments DTX3L expression. Functionally, DTX3L regulates ISG15 conjugation, antiviral gene programs, and DNA damage repair, placing it at the nexus of innate immunity and genome stability.
In the HEK293T background, which maintains intact interferon and NF-??B signaling circuits, DTX3L knockout provides a clean genetic platform to dissect ubiquitin-dependent immune regulation. The model permits detailed mapping of DTX3L?CPARP9 interaction networks, substrate identification by ubiquitin proteomics, and interrogation of signaling crosstalk between DNA damage and antiviral responses without interference from endogenous DTX3L.
Applications include Western blot analysis of downstream ubiquitination events, co-immunoprecipitation to probe PARP9 complex assembly, RT-qPCR profiling of interferon-stimulated genes, and immunofluorescence tracking of chromatin-associated DTX3L. These cells are also ideal for antiviral compound screening, DNA damage response quantification, and validation of DTX3L as a therapeutic target in cancer or viral pathogenesis. For additional technical information, please contact Ascent Research.
